Investigation Report on China Budesonide Market
DUBLIN, March 25, 2014 /PRNewswire/ –
Research and Markets (
http://www.researchandmarkets.com/research/s3kv36/investigation) has announced the
addition of the “Investigation Report on China Budesonide Market”
[http://www.researchandmarkets.com/research/s3kv36/investigation ] report to their
Asthma and allergic rhinitis are both very common diseases in the world today. As the
global atmosphere becomes more and more seriously contaminated, incidence of these
diseases increases year by year.
Budesonide inhalation suspension (trade name “”Pulmicort Respules”") developed by
Astra Zeneca was approved to market by FDA for asthma treatment in August 2000. It
obtained import approval in China in November 2001. Statistics shows that there are more
than 30 million asthma patients and over 0.3 billion people suffering from allergic
rhinitis in China. According to CRI’s investigation on certain sample hospital market in
China, the CAGR of sales value of budesonide surpassed 30% from 2005 to 2010. Since 2011,
market growth has slowed down, but it still maintains an annual growth rate of 18%.
In April 2013, the patent protection of asthma drug “”Pulmicort Respules”" produced by
Astra Zeneca was sentenced invalid in an U.S. regional court. Industry insiders think that
this has paved the way for generic drug to occupy the market.
According to CRI’s market investigation, budesonide products in Chinese market are
still mainly imported drugs from Astra Zeneca, but there are already some Chinese
enterprises, such as Lunan Better Pharmaceutical Co., Ltd., Humanwell Healthcare (Group)
Co., Ltd. and Shanghai Sine Promod Pharmaceutical Co., Ltd., producing budesonide APIs and
On January 15, 2013 Santarus, Inc. announced that FDA has ratifies the usage of Uceris
sustained release tablets in alleviating symptoms of mild – moderate active ulcerative
colitis. Uceris is a new drug developed by Santarus, Inc. and Cosmo Technologies Limited,
a subsidiary of Cosmo Pharmaceuticals S.p.A. This is a new oral tablet, and its main
ingredient is budesonide.
As Chinese economy develops and its environment worsens, the number of asthma and
allergic rhinitis patients in China will continue to rise in the next few years.
Furthermore, more indications may emerge in China. Consequently, market size of budesonide
in China will therefore continue to grow.
Key Topics Covered:
1 Relevant Concepts of Budesonide
2 Market Overview of Budesonide in China
3 Investigation on Sales Value of Budesonide in China, 2009-2013
4 Investigation on Market Share of Major Budesonide Manufacturers in China, 2009-2013
5 Investigation on Market Size of Budesonide by Dosage Form in China, 2009-2013
6 Reference Price of Budesonide Produced by Different Enterprises in China Hospital
7 Analysis on Major Budesonide Manufacturers in China, 2009-2013
8 Prospect of China Budesonide Market, 2014-2018
- AstraZeneca Australia - AstraZeneca plc. - Lunan Better Pharmaceutical Co., Ltd. - Synmosa Biopharma Corp.
For more information visit
Media Contact: Laura Wood , +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets